美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Alumis Inc.

9.18

-0.7200-7.27%

盤後：9.250.0700+0.76%19:46 EDT

成交量：342.43萬

成交額：3,190.60萬

市值：11.84億

市盈率：-2.42

高：10.11

開：9.99

低：9.14

收：9.90

52周最高：31.35

52周最低：3.76

股本：1.29億

流通股本：1.04億

量比：0.72

換手率：3.29%

股息：- -

股息率：- -

每股收益(TTM):-3.8005

每股收益(LYR):-2.8616

淨資產收益率：-93.65%

總資產收益率：-45.34%

市淨率：2.62

市盈率(LYR):-3.21

資料載入中...

總覽公司新聞公告

美國研究綜述-Adobe、戴爾科技、Zscaler

美國研究綜述-Adobe、戴爾科技、Zscaler

儘管臨床試驗未達預期，Alumis仍計劃開展紅斑狼瘡晚期研究

Alumis狼瘡藥物未能達到中期試驗目標

Alumis公布Envudeucitinib治療系統性紅斑狼瘡（SLE）2B期臨床試驗的初步結果

Alumis：干擾素基因高表達亞組響應強勁，為Envudeucitinib在系統性紅斑狼瘡中的三期臨床開發提供有力支撐

Alumis旗下Envudeucitinib在兩項三期試驗中展現皮膚清除、生活質量及銀屑病症狀早期顯著改善，凸顯其作為斑塊狀銀屑病一線口服療法的潛力

Alumis持續推進Envudeucitinib長期療效與安全性評估：Onward3長期擴展試驗進行中

Alumis：Envudeucitinib展現強勁皮膚清除效果，兩項試驗中從第16周至第24周均實現高閾值臨床應答

Alumis公布Envudeucitinib安全性數據：與二期項目一致，未出現新的安全信號

Alumis公布Envudeucitinib治療中重度斑塊型銀屑病三期數據，將於2026年AAD年會作重磅報告

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/ALMS/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ALMS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":9.18,"timestamp":1789156800000,"preClose":9.9,"halted":0,"volume":3424333,"hourTrading":{"tag":"盘后","latestPrice":9.25,"preClose":9.18,"latestTime":"19:46 EDT","volume":80105,"amount":740734.742,"timestamp":1789170377826,"change":0.07,"changeRate":0.007625,"amplitude":0.025054},"delay":0,"changeRate":-0.0727272727272728,"floatShares":104000000,"shares":129000000,"eps":-3.800544,"marketStatus":"休市中","change":-0.72,"latestTime":"09-11 16:00:00 EDT","open":9.99,"high":10.105,"low":9.14,"amount":31906003.570188,"amplitude":0.097475,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.800544,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":9.9,"preHourTrading":{"tag":"盘前","latestPrice":9.91,"preClose":9.9,"latestTime":"09:27 EDT","volume":4239,"amount":42618.308301,"timestamp":1789133260037,"change":0.01,"changeRate":0.00101,"amplitude":0.020354},"postHourTrading":{"tag":"盘后","latestPrice":9.25,"preClose":9.18,"latestTime":"19:46 EDT","volume":80105,"amount":740734.742,"timestamp":1789170377826,"change":0.07,"changeRate":0.007625,"amplitude":0.025054},"volumeRatio":0.723616872171578,"impliedVol":0.7775,"impliedVolPercentile":0.1594},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","floatShares":104000000,"roa":"-45.34%","roe":"-93.65%","lyrEps":-2.861649,"volumeRatio":0.723616872171578,"shares":129000000,"dividePrice":0,"high":10.105,"amplitude":0.097475,"preClose":9.9,"low":9.14,"week52Low":3.76,"pbRate":"2.62","psRate":"160.07","week52High":31.35,"institutionHeld":0,"latestPrice":9.18,"eps":-3.800544,"divideRate":0,"volume":3424333,"delay":0,"ttmEps":-3.800544,"open":9.99,"prevYearClose":9.76,"prevWeekClose":11.1,"prevMonthClose":21.81,"prevQuarterClose":28.14,"fiveDayClose":11.36,"twentyDayClose":24.41,"sixtyDayClose":22.32},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALMS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"ALMS","fiscalQuarterEnding":"2026/06","expectedEps":-0.7,"name":null,"time":"盤後","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-0.78},{"market":"US","date":"2026-05-14","symbol":"ALMS","fiscalQuarterEnding":"2026/03","expectedEps":-0.79,"name":null,"time":"盤後","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-0.74},{"market":"US","date":"2026-03-19","symbol":"ALMS","fiscalQuarterEnding":"2025/12","expectedEps":-0.97,"name":null,"time":"盤後","type":"earning","dateTimestamp":1773892800000,"reportTimeType":"post","actualEps":-0.95},{"market":"US","date":"2025-11-13","symbol":"ALMS","fiscalQuarterEnding":"2025/09","expectedEps":-0.92,"name":null,"time":"盤後","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-1.06},{"market":"US","date":"2025-08-13","symbol":"ALMS","fiscalQuarterEnding":"2025/06","expectedEps":-1.11,"name":null,"time":"盤後","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-1.17}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALMS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALMS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.4,"hold":0.1,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4,"analysts":10,"updateTime":1788408000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALMS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALMS","date":"2026-09-11","current":-2.415444,"percent":0.529837,"low":-16.271116,"twenty":-12.24255,"median":-3.12559,"eighty":-1.174396,"high":-0.443678,"avg":-5.265068,"sd":5.010088,"marketCap":1281408866},"quantilePoints":[{"date":"2024-06-28","current":-4.084559,"twenty":-4.913756,"median":-4.913756,"eighty":-4.416238,"marketCap":689534895},{"date":"2024-07-05","current":-3.516406,"twenty":-4.747917,"median":-3.851156,"eighty":-3.59564,"marketCap":593622147},{"date":"2024-07-12","current":-3.405847,"twenty":-4.063676,"median":-3.825051,"eighty":-3.58397,"marketCap":574958044},{"date":"2024-07-19","current":-4.023985,"twenty":-4.026561,"median":-3.851156,"eighty":-3.52869,"marketCap":679309112},{"date":"2024-07-26","current":-4.023985,"twenty":-4.117224,"median":-3.947896,"eighty":-3.58397,"marketCap":679309112},{"date":"2024-08-02","current":-4.178507,"twenty":-4.123137,"median":-3.980142,"eighty":-3.620209,"marketCap":705394582},{"date":"2024-08-09","current":-3.850149,"twenty":-4.108328,"median":-3.938677,"eighty":-3.693301,"marketCap":649962958},{"date":"2024-08-16","current":-3.683794,"twenty":-4.085032,"median":-3.914533,"eighty":-3.659692,"marketCap":696362265},{"date":"2024-08-23","current":-3.672282,"twenty":-4.078883,"median":-3.855481,"eighty":-3.667968,"marketCap":694186133},{"date":"2024-08-30","current":-3.655014,"twenty":-4.050383,"median":-3.84693,"eighty":-3.659692,"marketCap":690921935},{"date":"2024-09-06","current":-3.442045,"twenty":-4.027205,"median":-3.798947,"eighty":-3.608967,"marketCap":650663491},{"date":"2024-09-13","current":-3.33556,"twenty":-4.023985,"median":-3.741353,"eighty":-3.511116,"marketCap":630534270},{"date":"2024-09-20","current":-3.301025,"twenty":-4.023985,"median":-3.709695,"eighty":-3.405847,"marketCap":624005873},{"date":"2024-09-27","current":-3.211808,"twenty":-3.980142,"median":-3.685233,"eighty":-3.395997,"marketCap":607140850},{"date":"2024-10-04","current":-2.803137,"twenty":-3.959602,"median":-3.672282,"eighty":-3.303903,"marketCap":529888161},{"date":"2024-10-11","current":-2.978693,"twenty":-3.946725,"median":-3.656453,"eighty":-3.263611,"marketCap":563074175},{"date":"2024-10-18","current":-3.462191,"twenty":-3.930629,"median":-3.608967,"eighty":-3.220442,"marketCap":654471723},{"date":"2024-10-25","current":-3.424777,"twenty":-3.915649,"median":-3.608753,"eighty":-3.22332,"marketCap":647399293},{"date":"2024-11-01","current":-3.254977,"twenty":-3.914533,"median":-3.516406,"eighty":-3.231953,"marketCap":615301345},{"date":"2024-11-08","current":-3.459313,"twenty":-3.86344,"median":-3.50536,"eighty":-3.240587,"marketCap":653927690},{"date":"2024-11-15","current":-2.016571,"twenty":-3.859807,"median":-3.465068,"eighty":-3.22332,"marketCap":481504843},{"date":"2024-11-22","current":-2.155567,"twenty":-3.851156,"median":-3.454996,"eighty":-3.18015,"marketCap":514693313},{"date":"2024-11-29","current":-2.109995,"twenty":-3.85035,"median":-3.444923,"eighty":-3.067334,"marketCap":503811848},{"date":"2024-12-06","current":-2.050751,"twenty":-3.847574,"median":-3.439167,"eighty":-2.978693,"marketCap":489665943},{"date":"2024-12-13","current":-1.911755,"twenty":-3.823752,"median":-3.419021,"eighty":-2.94646,"marketCap":456477473},{"date":"2024-12-20","current":-2.009736,"twenty":-3.802749,"median":-3.405847,"eighty":-2.329653,"marketCap":479872624},{"date":"2024-12-27","current":-1.836561,"twenty":-3.764391,"median":-3.395997,"eighty":-2.153744,"marketCap":438523055},{"date":"2025-01-03","current":-1.925427,"twenty":-3.741353,"median":-3.367218,"eighty":-2.142807,"marketCap":459741913},{"date":"2025-01-10","current":-1.595028,"twenty":-3.741353,"median":-3.312536,"eighty":-2.023407,"marketCap":380851289},{"date":"2025-01-17","current":-1.745417,"twenty":-3.740777,"median":-3.298147,"eighty":-1.989684,"marketCap":416760124},{"date":"2025-01-24","current":-1.522113,"twenty":-3.738475,"median":-3.27944,"eighty":-1.964163,"marketCap":363440944},{"date":"2025-01-31","current":-1.704402,"twenty":-3.735597,"median":-3.263611,"eighty":-1.93682,"marketCap":406966805},{"date":"2025-02-07","current":-1.291973,"twenty":-3.709695,"median":-3.247782,"eighty":-1.911755,"marketCap":308489544},{"date":"2025-02-14","current":-1.187157,"twenty":-3.703939,"median":-3.22332,"eighty":-1.873019,"marketCap":283462173},{"date":"2025-02-21","current":-1.178042,"twenty":-3.690125,"median":-3.211808,"eighty":-1.829725,"marketCap":281285880},{"date":"2025-02-28","current":-1.059555,"twenty":-3.68437,"median":-3.162882,"eighty":-1.759544,"marketCap":252994070},{"date":"2025-03-07","current":-1.111963,"twenty":-3.676887,"median":-3.070787,"eighty":-1.711693,"marketCap":265507755},{"date":"2025-03-14","current":-1.041326,"twenty":-3.672858,"median":-3.006033,"eighty":-1.678881,"marketCap":248641484},{"date":"2025-03-21","current":-0.693421,"twenty":-3.667968,"median":-2.978693,"eighty":-1.565406,"marketCap":204027476},{"date":"2025-03-28","current":-1.042906,"twenty":-3.659692,"median":-2.965742,"eighty":-1.505251,"marketCap":306857324},{"date":"2025-04-04","current":-1.85837,"twenty":-3.65559,"median":-2.803137,"eighty":-1.500694,"marketCap":546793636},{"date":"2025-04-11","current":-1.198232,"twenty":-3.63199,"median":-2.286587,"eighty":-1.463027,"marketCap":352559478},{"date":"2025-04-17","current":-0.924562,"twenty":-3.622781,"median":-2.176074,"eighty":-1.280365,"marketCap":272036635},{"date":"2025-04-25","current":-0.791425,"twenty":-3.613572,"median":-2.146452,"eighty":-1.183511,"marketCap":232863359},{"date":"2025-05-02","current":-0.848748,"twenty":-3.60871,"median":-2.125945,"eighty":-1.162092,"marketCap":249729630},{"date":"2025-05-09","current":-0.930109,"twenty":-3.590112,"median":-2.016571,"eighty":-1.140673,"marketCap":273668854},{"date":"2025-05-16","current":-0.890525,"twenty":-3.561975,"median":-1.997203,"eighty":-1.105127,"marketCap":305759157},{"date":"2025-05-23","current":-0.766929,"twenty":-3.530406,"median":-1.968721,"eighty":-1.070948,"marketCap":263322832},{"date":"2025-05-30","current":-0.619565,"twenty":-3.51429,"median":-1.964163,"eighty":-1.045883,"marketCap":212725677},{"date":"2025-06-06","current":-0.530829,"twenty":-3.506511,"median":-1.95277,"eighty":-1.037224,"marketCap":182258572},{"date":"2025-06-13","current":-0.503891,"twenty":-3.48667,"median":-1.925427,"eighty":-0.984896,"marketCap":173009629},{"date":"2025-06-20","current":-0.476954,"twenty":-3.466829,"median":-1.916313,"eighty":-0.943233,"marketCap":163760687},{"date":"2025-06-27","current":-0.522906,"twenty":-3.464493,"median":-1.909477,"eighty":-0.920124,"marketCap":179538295},{"date":"2025-07-03","current":-0.538752,"twenty":-3.462191,"median":-1.878715,"eighty":-0.88573,"marketCap":184978849},{"date":"2025-07-11","current":-0.564105,"twenty":-3.459313,"median":-1.85837,"eighty":-0.848748,"marketCap":193683736},{"date":"2025-07-18","current":-0.556182,"twenty":-3.450679,"median":-1.833144,"eighty":-0.808067,"marketCap":190963459},{"date":"2025-07-25","current":-0.611642,"twenty":-3.444923,"median":-1.819538,"eighty":-0.791425,"marketCap":210005399},{"date":"2025-08-01","current":-0.65601,"twenty":-3.444923,"median":-1.768203,"eighty":-0.766929,"marketCap":225238952},{"date":"2025-08-08","current":-1.301335,"twenty":-3.442045,"median":-1.745417,"eighty":-0.761839,"marketCap":446809517},{"date":"2025-08-15","current":-2.007939,"twenty":-3.439167,"median":-1.743138,"eighty":-0.765537,"marketCap":456842285},{"date":"2025-08-22","current":-2.103991,"twenty":-3.427655,"median":-1.761367,"eighty":-0.766929,"marketCap":478695789},{"date":"2025-08-29","current":-2.14973,"twenty":-3.424777,"median":-1.805264,"eighty":-0.766929,"marketCap":489102219},{"date":"2025-09-05","current":-2.103991,"twenty":-3.415567,"median":-1.826307,"eighty":-0.771366,"marketCap":478695789},{"date":"2025-09-12","current":-1.994217,"twenty":-3.40866,"median":-1.836561,"eighty":-0.773109,"marketCap":453720356},{"date":"2025-09-19","current":-1.9622,"twenty":-3.406179,"median":-1.867544,"eighty":-0.787793,"marketCap":446435855},{"date":"2025-09-26","current":-1.824983,"twenty":-3.405847,"median":-1.875296,"eighty":-0.795863,"marketCap":415216564},{"date":"2025-10-03","current":-1.811262,"twenty":-3.397967,"median":-1.860219,"eighty":-0.799931,"marketCap":412094635},{"date":"2025-10-10","current":-2.071974,"twenty":-3.391392,"median":-1.873019,"eighty":-0.803629,"marketCap":471411288},{"date":"2025-10-17","current":-2.108565,"twenty":-3.371823,"median":-1.884428,"eighty":-0.807327,"marketCap":479736432},{"date":"2025-10-24","current":-2.108565,"twenty":-3.341892,"median":-1.893592,"eighty":-0.812505,"marketCap":479736432},{"date":"2025-10-31","current":-2.131434,"twenty":-3.317141,"median":-1.904969,"eighty":-0.82249,"marketCap":484939647},{"date":"2025-11-07","current":-2.158878,"twenty":-3.30563,"median":-1.911755,"eighty":-0.843135,"marketCap":491183505},{"date":"2025-11-14","current":-2.422653,"twenty":-3.301601,"median":-1.918592,"eighty":-0.848547,"marketCap":551197167},{"date":"2025-11-21","current":-2.946741,"twenty":-3.29642,"median":-1.93682,"eighty":-0.86502,"marketCap":722402348},{"date":"2025-11-28","current":-3.266113,"twenty":-3.290089,"median":-1.953052,"eighty":-0.869088,"marketCap":800697401},{"date":"2025-12-05","current":-3.534386,"twenty":-3.297571,"median":-1.962042,"eighty":-0.870197,"marketCap":866465244},{"date":"2025-12-12","current":-4.943882,"twenty":-3.336738,"median":-1.966442,"eighty":-0.879813,"marketCap":1212007408},{"date":"2025-12-19","current":-4.709675,"twenty":-3.399937,"median":-1.972322,"eighty":-0.888607,"marketCap":1154591037},{"date":"2025-12-26","current":-4.854457,"twenty":-3.410963,"median":-1.990368,"eighty":-0.898223,"marketCap":1190084794},{"date":"2026-01-02","current":-4.156097,"twenty":-3.436865,"median":-1.996504,"eighty":-0.911618,"marketCap":1018879613},{"date":"2026-01-09","current":-7.741582,"twenty":-3.449528,"median":-2.003365,"eighty":-0.920124,"marketCap":1897872066},{"date":"2026-01-16","current":-12.290084,"twenty":-3.466829,"median":-2.013154,"eighty":-0.925671,"marketCap":3012950964},{"date":"2026-01-23","current":-13.362987,"twenty":-3.516406,"median":-2.019374,"eighty":-0.930109,"marketCap":3275976472},{"date":"2026-01-30","current":-13.647739,"twenty":-3.577828,"median":-2.030809,"eighty":-0.937506,"marketCap":3345784190},{"date":"2026-02-06","current":-13.393497,"twenty":-3.626234,"median":-2.053678,"eighty":-0.942816,"marketCap":3283455871},{"date":"2026-02-13","current":-13.6274,"twenty":-3.672282,"median":-2.062826,"eighty":-0.944902,"marketCap":3340797925},{"date":"2026-02-20","current":-14.850306,"twenty":-3.690125,"median":-2.071974,"eighty":-0.965612,"marketCap":3640597141},{"date":"2026-02-27","current":-15.244382,"twenty":-3.739051,"median":-2.087982,"eighty":-0.981145,"marketCap":3737206037},{"date":"2026-03-06","current":-14.054527,"twenty":-3.801818,"median":-2.103991,"eighty":-0.986058,"marketCap":3445509501},{"date":"2026-03-13","current":-12.727381,"twenty":-3.85035,"median":-2.108565,"eighty":-0.99467,"marketCap":3120155674},{"date":"2026-03-20","current":-13.002303,"twenty":-3.914756,"median":-2.117713,"eighty":-1.01599,"marketCap":3163785497},{"date":"2026-03-27","current":-13.758909,"twenty":-3.96371,"median":-2.12686,"eighty":-1.031756,"marketCap":3347886444},{"date":"2026-04-02","current":-11.882219,"twenty":-4.025273,"median":-2.141239,"eighty":-1.038592,"marketCap":2891240839},{"date":"2026-04-10","current":-11.991997,"twenty":-4.096739,"median":-2.146452,"eighty":-1.041326,"marketCap":2917952699},{"date":"2026-04-17","current":-13.068872,"twenty":-4.165061,"median":-2.15037,"eighty":-1.042274,"marketCap":3179983325},{"date":"2026-04-24","current":-13.5864,"twenty":-4.472062,"median":-2.155567,"eighty":-1.044692,"marketCap":3305910664},{"date":"2026-05-01","current":-12.906818,"twenty":-4.742038,"median":-2.161164,"eighty":-1.045883,"marketCap":3140551531},{"date":"2026-05-08","current":-12.420656,"twenty":-4.831463,"median":-2.172599,"eighty":-1.054086,"marketCap":3022256152},{"date":"2026-05-15","current":-13.226323,"twenty":-4.877452,"median":-2.191451,"eighty":-1.062289,"marketCap":3140127467},{"date":"2026-05-22","current":-11.905302,"twenty":-5.029048,"median":-2.200043,"eighty":-1.070948,"marketCap":2826497196},{"date":"2026-05-29","current":-11.491811,"twenty":-7.697296,"median":-2.214811,"eighty":-1.081885,"marketCap":2728328372},{"date":"2026-06-05","current":-10.949441,"twenty":-10.746475,"median":-2.229773,"eighty":-1.094189,"marketCap":2599561472},{"date":"2026-06-12","current":-11.223311,"twenty":-10.767935,"median":-2.309816,"eighty":-1.101025,"marketCap":2664582382},{"date":"2026-06-18","current":-12.377862,"twenty":-10.942997,"median":-2.358363,"eighty":-1.105127,"marketCap":2938690139},{"date":"2026-06-26","current":-13.441123,"twenty":-11.434889,"median":-2.409687,"eighty":-1.106494,"marketCap":3191124259},{"date":"2026-07-02","current":-14.305694,"twenty":-11.51629,"median":-2.443671,"eighty":-1.111963,"marketCap":3396386347},{"date":"2026-07-10","current":-16.271116,"twenty":-11.77244,"median":-2.7977,"eighty":-1.135362,"marketCap":3863006994},{"date":"2026-07-17","current":-14.622524,"twenty":-11.882219,"median":-2.91667,"eighty":-1.139306,"marketCap":3471606615},{"date":"2026-07-24","current":-15.197115,"twenty":-11.985852,"median":-2.970059,"eighty":-1.141585,"marketCap":3608023034},{"date":"2026-07-31","current":-15.546165,"twenty":-12.051591,"median":-2.978693,"eighty":-1.145231,"marketCap":3690892821},{"date":"2026-08-07","current":-14.928615,"twenty":-12.229666,"median":-3.006033,"eighty":-1.151611,"marketCap":3544277044},{"date":"2026-08-14","current":-13.30798,"twenty":-12.354486,"median":-3.070787,"eighty":-1.160269,"marketCap":3159514183},{"date":"2026-08-21","current":-6.740728,"twenty":-12.30227,"median":-3.108556,"eighty":-1.162092,"marketCap":2958889563},{"date":"2026-08-28","current":-6.843932,"twenty":-12.28999,"median":-3.129848,"eighty":-1.162092,"marketCap":3004191897},{"date":"2026-09-04","current":-3.349723,"twenty":-12.282955,"median":-3.137731,"eighty":-1.167561,"marketCap":1470384315},{"date":"2026-09-11","current":-2.919213,"twenty":-12.24255,"median":-3.12559,"eighty":-1.174396,"marketCap":1281408866}],"updateTime":1789251377839},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALMS\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664942068","title":"美國研究綜述-Adobe、戴爾科技、Zscaler","url":"https://stock-news.laohu8.com/highlight/detail?id=2664942068","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664942068?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 15:47","pubTimestamp":1788335272,"startTime":"0","endTime":"0","summary":"美国研究综述-Adobe、戴尔科技、Zscaler路透9月2日-周三，华尔街证券分析师调整了包括Adobe、戴尔科技和Zscaler在内的多家美国上市公司评级及目标股价。股票条目按字母顺序排列。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nL4S44U0MW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADBE","RKLB","SPAM","MDB","REZ","KYMR","HAWK","USAR","SUNB","PSWD","CLOD","MMED","MNSH","BRZE","PALD","EYPT","USGG","ENOV","XLRE","CRK","RNTY","KNF","SAIC","WELL","EIX","PANW","DOCU","PKB","ALMS","NB","ASTS","GWRE","PL","MDT","PSCM","GTLB","AMRZ","ZS","ESI","MTRN","ORCL","REA","SRE","DELL","ASO","FXL","IPX.AU","ALM","MLM","OGE"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2664894205","title":"美國研究綜述-Adobe、戴爾科技、Zscaler","url":"https://stock-news.laohu8.com/highlight/detail?id=2664894205","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664894205?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 15:47","pubTimestamp":1788335272,"startTime":"0","endTime":"0","summary":"美国研究综述-Adobe、戴尔科技、Zscaler路透9月2日-周三，华尔街证券分析师调整了包括Adobe、戴尔科技和Zscaler在内的多家美国上市公司评级及目标股价。股票条目按字母顺序排列。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nL4T44U0MW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PANG","PL","ORCL","MDT","IGV","ESI","SAIC","CIBR","MDB","JPRE","BRZE","DOCU","OGE","DFGR","VGSR","FRI","EYPT","EIX","ALM","GWRE","MTRN","MLM","HAWK","MMED","REA","NB","ASTN","WELL","ASO","ADBG","KYMR","IPX.AU","PANW","ZS","SUNB","USAR","GTLB","CRK","ADBE","ALMS","REET","SRE","ENOV","ASTS","DELL","RKLB","KNF","FSPC","MNSH","AMRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664851728","title":"儘管臨床試驗未達預期，Alumis仍計劃開展紅斑狼瘡晚期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2664851728","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664851728?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 21:12","pubTimestamp":1788268356,"startTime":"0","endTime":"0","summary":"更新版 1-尽管临床试验未达预期，Alumis仍计划开展红斑狼疮晚期研究全文补充了细节和背景信息路透9月1日-Alumis公司周二表示，尽管该疗法未能达到中期临床试验的主要目标，但公司仍计划针对一小部分患者推进其用于治疗某种免疫相关疾病的实验性药物。据该公司称，这些患者被认为对针对干扰素通路的治疗反应更好，但在试验人群中所占比例低于预期，Alumis表示这导致了整体研究目标未达成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nL4S44T18C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664446855","title":"Alumis狼瘡藥物未能達到中期試驗目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2664446855","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664446855?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 19:34","pubTimestamp":1788262494,"startTime":"0","endTime":"0","summary":"Alumis狼疮药物未能达到中期试验目标路透9月1日-Alumis公司ALMS.O周二表示，其一款试验性药物在针对一种名为系统性红斑狼疮的慢性自身免疫性疾病患者开展的中期临床试验中，未能达到主要目标。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nL4S44T11H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102339511","title":"Alumis公布Envudeucitinib治療系統性紅斑狼瘡（SLE）2B期臨床試驗的初步結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1102339511","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102339511?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 19:31","pubTimestamp":1788262275,"startTime":"0","endTime":"0","summary":"Alumis公司今日对外宣布，其针对Envudeucitinib在系统性红斑狼疮适应症上开展的2B期临床试验，现已获得初步顶线数据。SLE作为一种复杂的自身免疫性疾病，长期以来缺乏高效且安全的治疗选择，而这一最新进展无疑为领域内带来了新的期待。该研究旨在评估Envudeucitinib在不同剂量方案下，对于中重度活动性SLE患者的疗效与安全性。这一里程碑式的进展，不仅可能重塑SLE的治疗格局，也为广大患者带来了潜在的创新疗法希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124847402","title":"Alumis：干擾素基因高表達亞組響應強勁，為Envudeucitinib在系統性紅斑狼瘡中的三期臨床開發提供有力支撐","url":"https://stock-news.laohu8.com/highlight/detail?id=1124847402","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124847402?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 19:31","pubTimestamp":1788262274,"startTime":"0","endTime":"0","summary":"Alumis公司公布的最新数据表明，在干扰素基因特征高表达的亚组患者中，Envudeucitinib展现出了强劲且稳健的治疗响应。这一积极结果，无疑为该公司正在推进的、针对系统性红斑狼疮的Envudeucitinib三期临床开发计划，注入了强有力的信心与数据支撑。基于此，Alumis公司正加速推进Envudeucitinib的后期临床研究，旨在为这一长期缺乏新疗法的疾病领域带来创新选择。此次数据的发布，或将为Envudeucitinib后续的临床路径及监管沟通奠定更为有利的基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138091701","title":"Alumis旗下Envudeucitinib在兩項三期試驗中展現皮膚清除、生活質量及銀屑病症狀早期顯著改善，凸顯其作為斑塊狀銀屑病一線口服療法的潛力","url":"https://stock-news.laohu8.com/highlight/detail?id=1138091701","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138091701?lang=zh_tw&edition=fundamental","pubTime":"2026-03-29 01:31","pubTimestamp":1774719072,"startTime":"0","endTime":"0","summary":"Alumis公司研发的Envudeucitinib在两项三期临床试验中取得突破性进展，该口服疗法在皮肤清除率、患者生活质量和银屑病核心症状方面均表现出早期且显著的改善效果。试验数据进一步验证了其作为斑块状银屑病前沿口服治疗方案的巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199051063","title":"Alumis持續推進Envudeucitinib長期療效與安全性評估：Onward3長期擴展試驗進行中","url":"https://stock-news.laohu8.com/highlight/detail?id=1199051063","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199051063?lang=zh_tw&edition=fundamental","pubTime":"2026-03-29 01:30","pubTimestamp":1774719029,"startTime":"0","endTime":"0","summary":"Alumis Inc. 目前正通过Onward3长期扩展试验，持续评估其在研药物Envudeucitinib的长期疗效与安全性表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197813725","title":"Alumis：Envudeucitinib展現強勁皮膚清除效果，兩項試驗中從第16周至第24周均實現高閾值臨床應答","url":"https://stock-news.laohu8.com/highlight/detail?id=1197813725","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197813725?lang=zh_tw&edition=fundamental","pubTime":"2026-03-29 01:30","pubTimestamp":1774719011,"startTime":"0","endTime":"0","summary":"Alumis公司宣布，其研究药物Envudeucitinib在两项临床试验中表现出强大的皮肤清除能力。从治疗的第16周开始，直至第24周，该药物持续达到了高标准的临床应答阈值，显示出显著且持久的疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144581026","title":"Alumis公布Envudeucitinib安全性數據：與二期項目一致，未出現新的安全信號","url":"https://stock-news.laohu8.com/highlight/detail?id=1144581026","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144581026?lang=zh_tw&edition=fundamental","pubTime":"2026-03-29 01:30","pubTimestamp":1774719010,"startTime":"0","endTime":"0","summary":"Alumis Inc. 近日披露了Envudeucitinib的最新临床数据，显示该药物在安全性与耐受性方面表现良好，结果与二期临床试验项目的数据保持一致。研究中未观察到新的安全性信号，进一步支持了该疗法的开发前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104384434","title":"Alumis公布Envudeucitinib治療中重度斑塊型銀屑病三期數據，將於2026年AAD年會作重磅報告","url":"https://stock-news.laohu8.com/highlight/detail?id=1104384434","media":"美股速递","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104384434?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 20:04","pubTimestamp":1773835493,"startTime":"0","endTime":"0","summary":"生物制药公司Alumis Inc.宣布，其主打候选药物Envudeucitinib用于中重度斑块型银屑病治疗的三期临床试验数据，已被遴选为2026年美国皮肤病学会年会的\"迟来突破\"口头报告环节。该环节专门展示具有高度临床价值的最新研究成果，意味着Envudeucitinib的三期数据获得了学术委员会对其科学重要性的认可。若三期数据积极，该药物有望在2026年AAD年会前后提交上市申请，切入规模可观的银屑病治疗市场。Alumis计划在2026年AAD年会上公布Envudeucitinib三期试验的详细疗效与安全性结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}]}}